Pharmacotherapeutic Approaches to Treatment of Muscular Dystrophies.

Biomolecules · 2023 · PMC10605463 · PMID 37892218

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

A phase 3 placebo-controlled clinical trial of this drug in DMD boys (aged 4–8 years) found it to be safe and tolerated, but functional data from the North Star Ambulatory Assessment (NSAA) criteria showed a nonsignificant trend of improvement in younger patients (<6 years) ( NCT03703882 ) [ 1 ].

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.